We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I refuseCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
November 21, 2023
Gosselies, Belgium
Bioxodes closes €12 million in Series A funding round
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage. Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023
August 23, 2023
London, United Kingdom
Head of Belgian Biotech Firm Wins Business Worldwide Magazine CEO Award
LONDON, Aug. 23, 2023 /PRNewswire/ -- In the 2023 Business Worldwide Magazine CEO Awards, Marc Dechamps, the CEO of Belgian biotech firm Bioxodes, receives an acknowledgment as he is named 'Biotechnology CEO of the Year - Europe'. Marc Dechamps was the outright winner in his category, for his ground-breaking work in the field of thrombo-inflammation or stroke.
April 26, 2023
Gosselies, Belgium
Bioxodes presents latest developments at key international conferences
• Bioxodes to give presentation at Bio€quity (May 14-16) and present posters at ESOC (May 24-26) and ISTH (June 24-28) • Company prepares Series A extension funding round for upcoming phase IIa and preparation of phase IIb clinical trials
December 15, 2022
Gosselies, Belgium
Bioxodes to present at Biotech Showcase™ 2023
Bioxodes to present at Biotech Showcase™ 2023 about its breakthrough drug candidate Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
October 18, 2022
Marche-en-Famenne, Belgium
Bioxodes appoints Marc Dechamps as new CEO
November 02, 2021
Marche-en-Famenne, Belgium
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
April 29, 2021
Marche-en-Famenne, Belgium
Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI
October 15, 2019
Marche-en-Famenne, Belgium
Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers
June 01, 2019
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients
June 01, 2015
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic
January 01, 2015
Marche-en-Famenne, Belgium
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
November 01, 2013
Marche-en-Famenne, Belgium
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva